Skip to main content
Clinical Trials/NL-OMON53980
NL-OMON53980
Recruiting
Not Applicable

Patients with knee pain caused by osteoarthritis: Comparison of conservative Medical Management with RadioFrequency ablation or chemical neurolysis of the genicular nerves with Phenol. - RADIOPHENO

Amsterdam UMC0 sites192 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Osteoarthritis
Sponsor
Amsterdam UMC
Enrollment
192
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Amsterdam UMC

Eligibility Criteria

Inclusion Criteria

  • 1\.Adult patients of both sexes, older then 35 years who are not a candidate for
  • TKA (total knee arthroplasty) due to young age, old age, comorbidity or
  • technical reasons.
  • 2\.OKS under 30 on a scale from 0 (severe function) to 48 points (satisfactory
  • 3\. Continued pain in the target knee that is moderate to severe (defined as NRS
  • \>\= 6 on an 11\-point NRS scale) either constantly or with motion despite at least
  • 3 months of conservative treatments. Conservative treatment can include: active
  • physiotherapy, pharmacological treatment of pain (acetaminophen or NSAIDs) and
  • intra\-articular corticosteroid infiltration.
  • 4\. Radiologic confirmation of arthritis for the target knee. Defined as the

Exclusion Criteria

  • 1\. Patient with prior ablation of the genicular nerves, prior partial,
  • resurfacing, or total knee arthroplasty of the target knee (residual hardware).
  • 2\. Patient with a history of neurovascular injury or recent trauma of the lower
  • extremities. 3\. Patient with chronic widespread pain. 4\. Polyneuropathy and/or
  • radicular pain in the lower extremities. 5\. Patient is currently implanted with
  • a neurostimulator. 6\. Local or systemic infection (bacteraemia). 7\.
  • Uncontrolled immune suppression. 8\. Intra\-articular injections (steroids,
  • hyaluronic acid, platelet enriched plasma, stem cell, \*) in the target knee
  • within 90 days from randomisation. 9\. Arthroscopic debridement/lavage into the
  • target knee within 180 days from randomisation. 10\. BMI\<18,5 kg/m2 and patients

Outcomes

Primary Outcomes

Not specified

Similar Trials